Developer docs
API playgroundTry for free, no card

Search company profiles

Civilization Ventures

Full company profile

uuid0000c8i

Namestring
Civilization Ventures
Legal namestring
Civilization Ventures Management, LLC
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Civilization Ventures is a San Francisco-based venture capital firm founded in 2017 by Shahram Seyedin-Noor that invests exclusively in early-stage life sciences companies across four thematic pillars: genomics and diagnostics, digital health, and synthetic biology (including gene and cell therapies). The firm operates a "mentor capital" model — combining early-stage funding with deep scientific due diligence, operational support from biopharma-experienced partners, and access to a global advisor network spanning Silicon Valley, Cambridge, New York, and Europe. A signature component is the Civilization Fellowship Program, which has trained 40+ PhDs, MDs, and MBAs from Harvard, Stanford, MIT, Caltech, Oxford, and Cambridge to become biotech investors and entrepreneurs, functioning as both a talent pipeline and a deal-sourcing channel.

The firm's product set comprises three fund vehicles — CV Fund I (a $1M pilot in 2017), CV Fund II ($35M raised in 2020), and the CV Opportunity Fund (raised in 2023, bringing total AUM to over $100M and currently over $200M) — alongside the Fellowship service offering. The investment team includes PhD-level Operating Partners in biophysics, chemistry, and precision oncology, an Investment Partner running scientific diligence, and a CFO overseeing fund administration. The core technology of the firm is its proprietary scientific due diligence methodology refined across 75+ investments.

Economically, Civilization Ventures operates a standard 2-and-20 fund model, earning management fees on AUM and carried interest from exits. Across 7 years the firm has completed 75 investments, 17 exits, and 3 unicorn outcomes (Rocket Pharma NASDAQ-listed, Omada Health NASDAQ IPO 2025, BilliontoOne $5B IPO 2025). Notable exits include Rewrite Therapeutics ($200M acquisition by Intellia, 2022), Lemonaid Health ($400M acquisition by 23andMe, 2021), Fluent BioSciences (acquired by Illumina, 2024), Singular Bio (acquired by Invitae, 2019), and Foresight Diagnostics ($450M acquisition by Natera, 2025). Customers, in the LP sense, are undisclosed family offices and strategic LPs, while end beneficiaries are scientific founders across the firm's thematic pillars.

Short descriptiontext

Civilization Ventures is a San Francisco-based early-stage venture capital firm founded in 2017 that invests across genomics, diagnostics, digital health, and synthetic biology, managing over $200M across three funds and a 40+ fellow Fellowship Program. It has completed 75 investments, 17 exits, and 3 unicorns in seven years.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, life sciences investing, biotech funding, early-stage investments, mentor capital
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management Fees
TypeManaged Services
Description

Civilization Ventures generates management fees from managing over $200M in capital across multiple funds (CV Fund I, CV Fund II at $35M, CV Opportunity Fund). The firm operates as a traditional VC with standard 2-and-20 fee structure implied by its fund vehicles.

civilizationventures.com
2Carried Interest (Carry)
TypeLicensing Royalties
Description

The firm earns carried interest from portfolio company exits. Notable exits generating returns include Rewrite Therapeutics (acquired by Intellia for $200M), Lemonaid Health ($400M acquisition by 23andMe), Foresight Diagnostics ($450M acquisition by Natera), Fluent Bio (acquired by Illumina), Singular Bio (acquired by Invitae), Rocket Pharma (NASDAQ listed), Omada Health (IPO 2025), and BilliontoOne ($5B valuation IPO 2025).

civilizationventures.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1CV Fellowship Program
Description

A fellowship program that trains PhDs to become entrepreneurs and investors in the life sciences sector. The program has graduated over 40 fellows.

civilizationventures.com
Core offering1 text field

Civilization Ventures is a venture capital firm that provides early-stage capital and 'mentor capital' support to scientific founders building companies in genomics and diagnostics, digital health, and synthetic biology. The firm manages three funds (CV Fund I, CV Fund II at $35M, and CV Opportunity Fund) with over $200M in total capital under management, and also runs the Civilization Fellowship Program training PhDs and MDs to become biotech investors and entrepreneurs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 3 unicorns achieved (Rocket Pharma, Omada Health IPO, BilliontoOne at $5B valuation) out of 75 investments in 7 years
+2 more records
Product overview1 text field

Civilization Ventures is a venture capital firm offering three core investment funds (CV Fund I, CV Fund II, and CV Opportunity Fund) with over $200M in total capital under management. The firm focuses on genomics, diagnostics, digital health, and synthetic biology sectors, with portfolio companies in AI-powered protein characterization, liquid biopsy testing, gene editing, and virtual care. Additionally, the firm offers the Civilization Fellowship Program, a training service for PhDs and MDs to become biotech entrepreneurs and investors. The firm has achieved 17 exits and 3 unicorns across 75 investments in 7 years.

Product and service4 records
1CV Fund I
CategoryVenture Capital Fund
Description

Venture capital fund investing in early-stage life sciences companies across genomics, diagnostics, digital health, and synthetic biology. The fund provides capital and mentorship to founders building companies in AI, liquid biopsy, gene editing, and cell therapies.

2CV Fund II
CategoryVenture Capital Fund
Description

Second venture capital fund of $35M raised in 2020 to lead pre-seed and seed investments in life sciences companies, including those working on COVID vaccine development and related therapeutics.

3CV Opportunity Fund
CategoryVenture Capital Fund
Description

Opportunity fund raised in 2023 to back founders as they scale, bringing total capital under management to over $100M. The fund supports portfolio companies through growth stages beyond initial investment.

4Civilization Fellowship Program
CategoryFellowship / Training Program
Description

A fellowship program training PhDs, MDs, and MBAs to become life sciences founders and investors. The program covers venture lifecycle including opportunity sourcing, due diligence, and investment memorandum writing. Over 40 fellows have graduated from institutions including Harvard, Stanford, MIT, Oxford, and Cambridge.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

KdT Ventures is an early-stage venture firm investing in computational biology, life sciences, and biotech at pre-seed and seed. It is the most directly comparable peer: similar fund size range, similar early-stage focus, and a co-investor alongside Civilization Ventures in deals such as Tacit Therapeutics.

TypeDirect peer
Description

Lux Capital is a science-and-technology-focused venture firm with a sizable life sciences and biotech portfolio investing from seed through growth. It is highly comparable in thesis (frontier science) and has co-invested with Civilization Ventures in Trial Library and other deals.

TypeBroad incumbent
Description

ARCH is one of the largest and most established early-stage life sciences venture firms, with a multi-decade track record founding and backing biotech, genomics, and therapeutics companies. It operates at much larger fund sizes but overlaps materially in thesis and stage.

TypeDirect peer
Description

Foresite Capital is a healthcare and life sciences-dedicated venture firm investing across stages with a focus on genomics, diagnostics, and data-driven therapeutics. It is a co-investor with Civilization Ventures in Foresight Diagnostics and shares the same investment domains.

TypeDirect peer
Description

Section 32 is a venture fund founded by Bill Maris focused on frontier science, technology, and healthcare. It is comparable in early-stage, science-first thesis, and in willingness to back ambitious life sciences and biotech founders before they are mainstream.

TypeDirect peer
Description

Atlas Venture is an early-stage life sciences venture firm that builds and funds biotech companies from inception through Series A. It is directly comparable in stage focus and therapeutics/diagnostics orientation, with deeper resources and longer history.

TypeBroad incumbent
Description

a16z Bio is the dedicated life sciences and bio fund within Andreessen Horowitz, investing at the intersection of biology and computation. It is a broad incumbent peer — far larger and broader in scope — but increasingly active in the same AI-meets-biology seed landscape.

TypeBroad incumbent
Description

RA Capital is a healthcare-focused investment manager with both public-market and private-venture operations across biotech, rare disease, and genomics. Comparable in domain (life sciences) and active in co-investments in CV's portfolio companies.

TypeBroad incumbent
Description

OrbiMed is one of the world's largest healthcare-dedicated investment firms, covering venture, growth, and public markets across therapeutics, medical devices, and diagnostics. Comparable in domain focus though at significantly larger fund sizes and broader stage coverage.

TypeDirect peer
Description

5AM Ventures is an early-stage venture firm focused on life sciences, founding and seeding biotech and platform companies. Directly comparable in stage (seed/Series A) and life sciences focus, with similar fund size profile to Civilization Ventures.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment93 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Civilization Ventures

Life Sciences Venture Capitalcivilizationventures.com

Civilization Ventures is a San Francisco-based early-stage venture capital firm founded in 2017 that invests across genomics, diagnostics, digital health, and synthetic biology, managing over $200M across three funds and a 40+ fellow Fellowship Program. It has completed 75 investments, 17 exits, and 3 unicorns in seven years.

What Civilization Ventures does

Civilization Ventures is a San Francisco-based venture capital firm founded in 2017 by Shahram Seyedin-Noor that invests exclusively in early-stage life sciences companies across four thematic pillars: genomics and diagnostics, digital health, and synthetic biology (including gene and cell therapies). The firm operates a "mentor capital" model — combining early-stage funding with deep scientific due diligence, operational support from biopharma-experienced partners, and access to a global advisor network spanning Silicon Valley, Cambridge, New York, and Europe. A signature component is the Civilization Fellowship Program, which has trained 40+ PhDs, MDs, and MBAs from Harvard, Stanford, MIT, Caltech, Oxford, and Cambridge to become biotech investors and entrepreneurs, functioning as both a talent pipeline and a deal-sourcing channel.

The firm's product set comprises three fund vehicles — CV Fund I (a $1M pilot in 2017), CV Fund II ($35M raised in 2020), and the CV Opportunity Fund (raised in 2023, bringing total AUM to over $100M and currently over $200M) — alongside the Fellowship service offering. The investment team includes PhD-level Operating Partners in biophysics, chemistry, and precision oncology, an Investment Partner running scientific diligence, and a CFO overseeing fund administration. The core technology of the firm is its proprietary scientific due diligence methodology refined across 75+ investments.

Economically, Civilization Ventures operates a standard 2-and-20 fund model, earning management fees on AUM and carried interest from exits. Across 7 years the firm has completed 75 investments, 17 exits, and 3 unicorn outcomes (Rocket Pharma NASDAQ-listed, Omada Health NASDAQ IPO 2025, BilliontoOne $5B IPO 2025). Notable exits include Rewrite Therapeutics ($200M acquisition by Intellia, 2022), Lemonaid Health ($400M acquisition by 23andMe, 2021), Fluent BioSciences (acquired by Illumina, 2024), Singular Bio (acquired by Invitae, 2019), and Foresight Diagnostics ($450M acquisition by Natera, 2025). Customers, in the LP sense, are undisclosed family offices and strategic LPs, while end beneficiaries are scientific founders across the firm's thematic pillars.

Civilization Ventures firmographics

Firmographics
Name
Civilization Ventures
Legal name
Civilization Ventures Management, LLC
Website
https://civilizationventures.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Civilization Ventures is a San Francisco-based early-stage venture capital firm founded in 2017 that invests across genomics, diagnostics, digital health, and synthetic biology, managing over $200M across three funds and a 40+ fellow Fellowship Program. It has completed 75 investments, 17 exits, and 3 unicorns in seven years.
Ownership category
akta.pro rank

Where Civilization Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Civilization Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Fund Management Fees: Civilization Ventures generates management fees from managing over $200M in capital across multiple funds (CV Fund I, CV Fund II at $35M, CV Opportunity Fund). The firm operates as a traditional VC with standard 2-and-20 fee structure implied by its fund vehicles.
  2. Carried Interest (Carry): The firm earns carried interest from portfolio company exits. Notable exits generating returns include Rewrite Therapeutics (acquired by Intellia for $200M), Lemonaid Health ($400M acquisition by 23andMe), Foresight Diagnostics ($450M acquisition by Natera), Fluent Bio (acquired by Illumina), Singular Bio (acquired by Invitae), Rocket Pharma (NASDAQ listed), Omada Health (IPO 2025), and BilliontoOne ($5B valuation IPO 2025).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Civilization Ventures product offering

Product offering

Core offering

Civilization Ventures is a venture capital firm that provides early-stage capital and 'mentor capital' support to scientific founders building companies in genomics and diagnostics, digital health, and synthetic biology. The firm manages three funds (CV Fund I, CV Fund II at $35M, and CV Opportunity Fund) with over $200M in total capital under management, and also runs the Civilization Fellowship Program training PhDs and MDs to become biotech investors and entrepreneurs.

Product overview

Civilization Ventures is a venture capital firm offering three core investment funds (CV Fund I, CV Fund II, and CV Opportunity Fund) with over $200M in total capital under management. The firm focuses on genomics, diagnostics, digital health, and synthetic biology sectors, with portfolio companies in AI-powered protein characterization, liquid biopsy testing, gene editing, and virtual care. Additionally, the firm offers the Civilization Fellowship Program, a training service for PhDs and MDs to become biotech entrepreneurs and investors. The firm has achieved 17 exits and 3 unicorns across 75 investments in 7 years.

Differentiator

Problem solved

Functional benefit

Brands

  • CV Fellowship Program: A fellowship program that trains PhDs to become entrepreneurs and investors in the life sciences sector. The program has graduated over 40 fellows.

Products and services

  • CV Fund I Venture capital fund investing in early-stage life sciences companies across genomics, diagnostics, digital health, and synthetic biology. The fund provides capital and mentorship to founders building companies in AI, liquid biopsy, gene editing, and cell therapies.
  • CV Fund II Second venture capital fund of $35M raised in 2020 to lead pre-seed and seed investments in life sciences companies, including those working on COVID vaccine development and related therapeutics.
  • CV Opportunity Fund Opportunity fund raised in 2023 to back founders as they scale, bringing total capital under management to over $100M. The fund supports portfolio companies through growth stages beyond initial investment.
  • Civilization Fellowship Program A fellowship program training PhDs, MDs, and MBAs to become life sciences founders and investors. The program covers venture lifecycle including opportunity sourcing, due diligence, and investment memorandum writing. Over 40 fellows have graduated from institutions including Harvard, Stanford, MIT, Oxford, and Cambridge.

Quantifiable outcome

  • 3 unicorns achieved (Rocket Pharma, Omada Health IPO, BilliontoOne at $5B valuation) out of 75 investments in 7 years
  • +2 more outcomes

Companies that use Civilization Ventures

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Civilization Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Civilization Ventures partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Civilization Ventures competitors and assessment

Company assessment

Direct peers

  • KdT Ventures: KdT Ventures is an early-stage venture firm investing in computational biology, life sciences, and biotech at pre-seed and seed. It is the most directly comparable peer: similar fund size range, similar early-stage focus, and a co-investor alongside Civilization Ventures in deals such as Tacit Therapeutics.
  • Lux Capital: Lux Capital is a science-and-technology-focused venture firm with a sizable life sciences and biotech portfolio investing from seed through growth. It is highly comparable in thesis (frontier science) and has co-invested with Civilization Ventures in Trial Library and other deals.
  • Foresite Capital: Foresite Capital is a healthcare and life sciences-dedicated venture firm investing across stages with a focus on genomics, diagnostics, and data-driven therapeutics. It is a co-investor with Civilization Ventures in Foresight Diagnostics and shares the same investment domains.
  • Section 32: Section 32 is a venture fund founded by Bill Maris focused on frontier science, technology, and healthcare. It is comparable in early-stage, science-first thesis, and in willingness to back ambitious life sciences and biotech founders before they are mainstream.
  • Atlas Venture: Atlas Venture is an early-stage life sciences venture firm that builds and funds biotech companies from inception through Series A. It is directly comparable in stage focus and therapeutics/diagnostics orientation, with deeper resources and longer history.
  • 5AM Ventures: 5AM Ventures is an early-stage venture firm focused on life sciences, founding and seeding biotech and platform companies. Directly comparable in stage (seed/Series A) and life sciences focus, with similar fund size profile to Civilization Ventures.

Broad incumbents

  • ARCH Venture Partners: ARCH is one of the largest and most established early-stage life sciences venture firms, with a multi-decade track record founding and backing biotech, genomics, and therapeutics companies. It operates at much larger fund sizes but overlaps materially in thesis and stage.
  • Andreessen Horowitz (a16z Bio): a16z Bio is the dedicated life sciences and bio fund within Andreessen Horowitz, investing at the intersection of biology and computation. It is a broad incumbent peer — far larger and broader in scope — but increasingly active in the same AI-meets-biology seed landscape.
  • RA Capital Management: RA Capital is a healthcare-focused investment manager with both public-market and private-venture operations across biotech, rare disease, and genomics. Comparable in domain (life sciences) and active in co-investments in CV's portfolio companies.
  • OrbiMed Advisors: OrbiMed is one of the world's largest healthcare-dedicated investment firms, covering venture, growth, and public markets across therapeutics, medical devices, and diagnostics. Comparable in domain focus though at significantly larger fund sizes and broader stage coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Civilization Ventures social profiles

Digital presence

Civilization Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Civilization Ventures leadership team

Management profile

Number of profiles

Profiles8 records

Civilization Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Civilization Ventures M&A and investment

M&A and investment

M&A

Investments93 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Civilization Ventures

What does Civilization Ventures do?

Civilization Ventures is a venture capital firm that provides early-stage capital and 'mentor capital' support to scientific founders building companies in genomics and diagnostics, digital health, and synthetic biology. The firm manages three funds (CV Fund I, CV Fund II at $35M, and CV Opportunity Fund) with over $200M in total capital under management, and also runs the Civilization Fellowship Program training PhDs and MDs to become biotech investors and entrepreneurs.

Is Civilization Ventures a public or private company?

Civilization Ventures is a private company. It is classified as venture growth investor backed and is currently operating.

When was Civilization Ventures founded?

Civilization Ventures was founded in 2017. It employs 1 to 10 people.

Where is Civilization Ventures based?

Civilization Ventures is headquartered in San Francisco, United States, in the North America region.

How does Civilization Ventures make money?

Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest (Carry).

Who are Civilization Ventures's main competitors?

Direct peers on record are KdT Ventures, Lux Capital, Foresite Capital, Section 32, Atlas Venture and 5AM Ventures. Broad incumbents are ARCH Venture Partners, Andreessen Horowitz (a16z Bio), RA Capital Management and OrbiMed Advisors.

Does Civilization Ventures have an API?

No public API is recorded for Civilization Ventures.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsInfinimmune Raises $75M in Series A FundingInfinimmune raised $75M in Series A funding co-led by Regeneron Ventures and Playground Global. The company will use the funds to accelerate clinical development of its atopic dermatitis programs IFX-101 and IFX-201, and advance its Anthrobody discovery platform.BioSpaceInfinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory DiseaseInfinimmune closed a $75 million Series A co-led by Regeneron Ventures and Playground Global. The funds will accelerate clinical development of two lead atopic dermatitis antibodies, IFX-101 and IFX-201, with first-in-human studies starting in 2027.Venture Capital Access OnlineInfinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory DiseaseInfinimmune closed a $75 million Series A co-led by Regeneron Ventures and Playground Global. The funds will accelerate clinical development of two lead antibodies for atopic dermatitis, with first-in-human studies starting in 2027. The company also entered a Merck collaboration in March 2026.BioWorldRinascera launches with two rare genetic skin disease therapiesRinascera Therapeutics secured initial funding to acquire two drugs for rare genetic skin diseases, despite stalled development with previous owners. The company, incubated by Olive Tree Capital, was named after the Latin root renasci.MorningstarSyntax Bio Announces Expanded Series A and Leadership AppointmentsSyntax Bio announced an expanded Series A bringing total funding to over $25 million, with proceeds supporting its Cellgorithm platform and pancreatic beta cell therapy for type 1 diabetes. The company also appointed new executives and board members to strengthen leadership.Wowtale[YC/시드] 10x 사이언스, 480만 달러 투자유치.. “AI가 만든 신약 후보, 제대로 골라낸다”10x Science, a startup founded in December 2025, closed a $4.8 million seed round led by Initialized Capital. The company's AI platform automates mass spectrometry analysis for drug candidates, aiming to solve the verification bottleneck in AI-driven drug discovery. It plans to expand partnerships and use the funds for hiring and R&D.TechCrunchAI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.10x Science, a biotech startup founded in December 2025 by three former Stanford researchers, announced a $4.8 million seed round led by Initialized Capital with participation from Y Combinator, Civilization Ventures, and Founder Factor to build AI-powered tools for analyzing mass spectrometry data in drug discovery. The company's platform addresses an emerging bottleneck in biopharma where AI generates numerous drug candidates but the characterization process required to evaluate them remains slow and labor-intensive. The founders, who previously studied cancer cell and immune system interactions under Nobel laureate Dr. Carolyn Bertozzi, are using the funding to hire engineers and expand their customer base among pharmaceutical companies and academic researchers.Venture Capital Access Online10x Science Raises $4.8M Seed to Build AI That Understands Proteins at the Molecular Level10x Science closed a $4.8M seed round led by Initialized Capital, with participation from Y Combinator and others. The company's AI platform automates protein characterization, delivering explainable molecular insights in minutes where manual workflows take months. The funding will support hiring and expanding partnerships with pharma and biotech firms.FinSMEs10x Science Raises $4.8M in Seed Funding10x Science, a San Francisco-based AI startup for protein characterization, closed a $4.8M seed round led by Initialized Capital. The company, founded in December 2025, offers automated molecular insights for drug development, with tens of thousands of biologic drugs in active development.BioSpaceIantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma TherapyIantrek closed a $42 million Series C to fund the U.S. launch of AlloFlo Uveo, a surgical solution for the uveoscleral pathway. The company cites a 2025 study showing a mean IOP reduction of 34% and medication use cut by over 60%. First-in-human trials for its next product are completed, with a 2026 launch expected.